DTC Ads May Extend Product Life Without Rx-To-OTC Switch – Pfizer’s Gelbert
This article was originally published in The Tan Sheet
Executive Summary
An increase in DTC advertising and brand name recognition for Rx drugs may prevent companies from feeling an urgent need to switch their drugs over-the-counter upon patent expiration
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning